Pulmonx stock falls 2.91 percent as revenue slips 5 percent

Published on 09/24/2026 at 00:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Pulmonx stock traded at USD 2.00 on September 23, 2026, below its USD 2.89 yearly high. The second-quarter loss narrowed to USD 10.1 million as annual guidance held.

Pulmonx stock, medical devices, second-quarter results, revenue guidance, Nasdaq, Illustration mit AI erstellt.

Pulmonx stock (ISIN US7458481014) fell 2.91 percent to USD 2.00 on Nasdaq on September 23, 2026, leaving the medical-device company below its USD 2.89 52-week high. The second-quarter report showed lower revenue but a narrower loss, creating a mixed operating picture for investors.

Revenue declined in Q2

Pulmonx generated worldwide revenue of USD 22.8 million in Q2 2026, down 5 percent from USD 23.9 million in Q2 2025, according to The Globe and Mail on July 29, 2026. The decline was linked to the absence of shipments to China, while international revenue excluding China increased 12 percent year over year.

The US contributed USD 14.2 million, a 4 percent year-over-year decline from USD 14.7 million. Sequentially, however, US revenue rose 7 percent from Q1 2026, giving the regional figure a stronger trajectory than the consolidated result.

Loss narrows while guidance holds

Net loss fell to USD 10.1 million in Q2 2026 from USD 15.2 million in the prior-year quarter, a 34 percent reduction. The loss per share narrowed to USD 0.24 from USD 0.38, while adjusted EBITDA loss declined to USD 5.1 million from USD 8.4 million, according to The Globe and Mail.

For the full year 2026, Pulmonx reiterated revenue guidance of USD 90 million to USD 92 million. MarketBeat reported that Q2 revenue of USD 22.76 million exceeded consensus of USD 22.39 million, while the USD 0.24 loss per share was narrower than the expected USD 0.28 loss, a USD 0.04 improvement against consensus.

Stock remains below yearly high

Pulmonx had a market capitalization of USD 84,474,400 on September 23, 2026. Its USD 2.00 share price stood USD 0.89 below the 52-week high of USD 2.89, a gap of 30.8 percent that keeps the latest quote well below the yearly peak.

The combination of a 5 percent revenue decline and a 34 percent reduction in net loss puts cost control beside commercial recovery at the center of the investment case. The next market test is whether revenue can move toward the reiterated USD 90 million to USD 92 million annual range.